Clinical Trial
doi: 10.1176/ajp.133.2.208.
Recent developments in the drug treatment of schizophrenia
- PMID: 766652
- DOI: 10.1176/ajp.133.2.208
Item in Clipboard
Clinical Trial
Recent developments in the drug treatment of schizophrenia
Am J Psychiatry.
1976 Feb.
Abstract
The author reviews six topics relevant to the drug treatment of schizophrenia. The quantitative effectiveness of promazine is of interest with respect to the structural models of the phenothiazines and the dopamine theory of schizophrenia. The quantitative effectiveness of antipsychotic drugs is also important in evaluating new agents and therefore relevant to a discussion of two newly released neuroleptics, molindone and loxapine. The author's discussion of high-dose treatment of typical acute schizophrenics or treatment-resistant patients reviews the available data and calls attention to the fact that these areas of pharmacologic research have not received sufficient attention.
Similar articles
-
The importance of dosage in antipsychotic drug administration--a review of dose-response studies.Psychopharmacologia. 1973;29(3):221-30. doi: 10.1007/BF00414036. Psychopharmacologia. 1973. PMID: 4144989 Review. No abstract available.
-
Schizophrenic subtypes defined by response to drugs and placebo.Dis Nerv Syst. 1968 May;29(5):Suppl:153-8. Dis Nerv Syst. 1968. PMID: 4876985 Clinical Trial. No abstract available.
-
Prolixin enanthate and thorazine-stelazine regimens in the treatment of schizophrenic patients. An experimental evaluation.Psychosomatics. 1971 May-Jun;12(3):186-90. doi: 10.1016/S0033-3182(71)71533-3. Psychosomatics. 1971. PMID: 4950862 Clinical Trial. No abstract available.
-
[Comparative study of 2 drugs and a placebo in chronic schizophrenia].Actual Pharmacol (Paris). 1969;22:1-18. Actual Pharmacol (Paris). 1969. PMID: 4927120 Clinical Trial. French. No abstract available.
-
Loxapine: a review of its pharmacological properties and therapeutic efficacy as an antipsychotic agent.Drugs. 1978 Mar;15(3):198-217. doi: 10.2165/00003495-197815030-00002. Drugs. 1978. PMID: 25167 Review.
Cited by
-
Intermittent drug techniques for schizophrenia.Cochrane Database Syst Rev. 2013 Jul 20;2013(7):CD006196. doi: 10.1002/14651858.CD006196.pub2. Cochrane Database Syst Rev. 2013. PMID: 23881657 Free PMC article.
-
Endogenous ligands of a putative LSD-serotonin receptor in the cerebrospinal fluid: higher level of LSD-displacing factors (LDF) in unmedicated psychotic patients.Psychopharmacology (Berl). 1977 Aug 31;54(1):9-16. doi: 10.1007/BF00426533. Psychopharmacology (Berl). 1977. PMID: 410064 No abstract available.
-
Treatment resistance in schizophrenia.BMJ. 1996 Feb 10;312(7027):325-6. doi: 10.1136/bmj.312.7027.325. BMJ. 1996. PMID: 8611817 Free PMC article. No abstract available.
-
Haloperidol plasma levels and clinical response in paranoid schizophrenics.Eur Arch Psychiatry Neurol Sci. 1984;234(4):231-6. doi: 10.1007/BF00381354. Eur Arch Psychiatry Neurol Sci. 1984. PMID: 6526061
-
A systematic review of the Soteria paradigm for the treatment of people diagnosed with schizophrenia.Schizophr Bull. 2008 Jan;34(1):181-92. doi: 10.1093/schbul/sbm047. Epub 2007 Jun 14. Schizophr Bull. 2008. PMID: 17573357 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
